Applied Therapeutics (APLT) to Release Quarterly Earnings on Thursday

Applied Therapeutics (NASDAQ:APLT) is projected to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Applied Therapeutics to post earnings of ($0.15) per share and revenue of $0.25 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Monday, November 10, 2025 at 4:00 PM ET.

Applied Therapeutics (NASDAQ:APLT) last issued its earnings results on Wednesday, August 13th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.02. On average, analysts expect Applied Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Applied Therapeutics Stock Performance

APLT opened at $1.02 on Tuesday. Applied Therapeutics has a one year low of $0.30 and a one year high of $10.62. The business’s 50 day moving average price is $0.83 and its 200 day moving average price is $0.56. The stock has a market capitalization of $146.17 million, a PE ratio of -2.23 and a beta of 2.08.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Applied Therapeutics stock. AQR Capital Management LLC acquired a new stake in shares of Applied Therapeutics Inc. (NASDAQ:APLT) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 572,311 shares of the company’s stock, valued at approximately $280,000. AQR Capital Management LLC owned about 0.40% of Applied Therapeutics as of its most recent SEC filing. 98.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Wall Street Zen raised shares of Applied Therapeutics to a “sell” rating in a research report on Saturday, July 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Applied Therapeutics in a research note on Tuesday, October 14th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $4.13.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.